Fig. 6.

PRDX-1 knockdown sensitises IR resistant NG2 positive cells in vivo. a Schematic of an intracerebral tumour-bearing mouse implanted with ¹²⁵I seeds. A gradient IR dose (fading line) was delivered to the tumour bed. B brain, S guide-screw, T tumour, n number of animals (adapted from [50]). b Tumour sizes in vivo before IR treatment (top panel) and after treatment with ¹²⁵I (bottom panel). c Histological staining at 19 weeks with H&E and anti-NG2 antibodies. Note the vascular lakes in the U251-NG2 control shRNA and numerous mitotic figures (arrowheads) in U251-NG2/PRDX-1 shRNA tumours, giant multinucleated cells (arrowheads). Scale bars in all (100 μm; magnification 400×), except rows stained for NG2 (200 μm; magnification 200×). d Densitometric quantified, Fold PRDX-1 change in tumour compared to normal brain tissue of mice receiving no treatment or ionizing radiation